Person:
ŞEVKET, OSMAN

Loading...
Profile Picture
Status
Organizational Units
Organizational Unit
Job Title
First Name
OSMAN
Last Name
ŞEVKET
Name
Email Address
Birth Date

Search Results

Now showing 1 - 10 of 44
  • PublicationMetadata only
    Granulosa cell tumor presenting with ovarian torsion and de novo borderline mucinous ovarian tumor in the contralateral ovary.
    (2015-01-01) ATES, SEDA; Sevket, OSMAN; SUDOLMUS, S; SONMEZ, FATMA CAVİDE; DANSUK, RAMAZAN; ATEŞ, SEDA; ŞEVKET, OSMAN; SÖNMEZ, FATMA CAVİDE; DANSUK, RAMAZAN
  • PublicationMetadata only
    The use of HbA1c as an aid in the diagnosis of gestational diabetes mellitus.
    (2014-11-01) Sevket, OSMAN; SEVKET, A; OZEL, A; DANSUK, RAMAZAN; KELEKCI, S; ŞEVKET, OSMAN; DANSUK, RAMAZAN
  • PublicationMetadata only
    Olgu sunumu: İzole tuba torsiyonu
    (2013-05-19) KILIC, GÖKHAN; Sarıoğlu, Aslı Elif; Şevket, OSMAN; Dane, Banu; Dansuk, RAMAZAN; KILIC, GÖKHAN; ŞEVKET, OSMAN; DANSUK, RAMAZAN
  • PublicationMetadata only
    Familial Swyer syndrome in two sisters with undeveloped uterus.
    (2014-08-01) ATES, SEDA; BATMAZ, G; SEVKET, OSMAN; MOLLA, T; Dane, B; ATEŞ, SEDA; ŞEVKET, OSMAN; KILIÇOĞLU DANE, PAKİZER BANU
  • PublicationOpen Access
    Effect of GnRH antagonists on clinical pregnancy rates in ovulation induction protocols with gonadotropins and intrauterine insemination.
    (2015-06-01) DANSUK, RAMAZAN; GONENC, AI; SUDOLMUS, S; YUCEL, O; Sevket, OSMAN; KÖROĞLU, N; DANSUK, RAMAZAN; ŞEVKET, OSMAN
    Introduction: Intrauterine insemination (IUI) after controlled ovarian hyperstimulation (COH) was applied to selected infertile patients to determine the effect of gonadotropin-releasing hormone (GnRH) antagonists in IUI cycles, in which recombinant follicle-stimulating hormone (rFSH) had been used for COH. Methods: This study was conducted between April 1, 2009 and June 10, 2009, and involved a total of 108 patients. These patients had primary or secondary infertility, which resulted in an indication for IUI, and they each received two cycles of ovarian stimulation treatment with clomiphene citrate. The patients were randomised into two groups--patients in group A received rFSH + GnRH antagonist (n = 45), while those in group B received only rFSH (n = 63). Results: The mean age of the patients was 31.84 ± 3.73 years and the mean body mass index (BMI) was 24.40 ± 1.88 kg/m(2). The mean age and BMI of the patients in groups A and B were not significantly different. There was no significant difference in the mean total rFSH dose administered (988.33 IU in group A and 871.83 IU in group B). When compared to group B, the mean number of follicles that were > 16 mm on the human chorionic gonadotropin (HCG) trigger day was significantly higher in group A (1.58 and 1.86, respectively; p < 0.05). When the two groups were compared, there were no statistically significant differences in the number of cancelled cycles due to premature luteinisation (none in group A vs. two in group B) and the rate of clinical pregnancy (8.9% in group A vs. 7.9% in group B). Conclusion: No significant improvement in the clinical pregnancy rates was observed when GnRH antagonists were used in COH + IUI cycles, despite the significant increase in the number of follicles that were > 16 mm on HCG trigger day.
  • PublicationMetadata only
    Is methotrexate administration needed for the treatment of caesarean section scar pregnancy in addition to suction curettage?
    (2014-04-01) Sevket, OSMAN; KESKIN, S; ATES, SEDA; MOLLA, T; DANSUK, RAMAZAN; YAZıCıOĞLU, HF; YUCEL, O; ŞEVKET, OSMAN; ATEŞ, SEDA; DANSUK, RAMAZAN
  • PublicationMetadata only
    Comparison of metabolic profile and abdominal fat distribution between karyotypically normal women with premature ovarian insufficiency and age matched controls.
    (2014-11-01) YILDIZ, S; ATES, SEDA; YESIL, GÖZDE; Sevket, OSMAN; MOLLA, T; ATEŞ, SEDA; YEŞİL, GÖZDE; ŞEVKET, OSMAN; YILDIZ, ŞEYMA
    Objective: We designed a prospective case-control study in order to investigate the lipid profiles, insulin sensitivity, presence of metabolic syndrome (MetS) and the abdominal fat distribution in karyotypically normal women with premature ovarian insufficiency (POI).
  • PublicationMetadata only
    Natural history of prenatal isolated muscular ventricular septal defects.
    (2014-06-01T00:00:00Z) EROL, O; Sevket, OSMAN; KESKIN, S; YAZıCıOĞLU, HF; GÜL, A; ŞEVKET, OSMAN
  • PublicationOpen Access
    Vaginal assisted laparoscopic sacrocervicopexy with anterior colpotomy (VALSAC): technique and mean 20 months outcomes
    (2020-12-01T00:00:00Z) ŞEVKET, OSMAN; TAKMAZ, TAHA; Sevket, A. C.; TOPRAK, ALİ; ÖZCAN, PINAR; ŞEVKET, OSMAN; TAKMAZ, TAHA; TOPRAK, ALİ; ÖZCAN, PINAR
    The main purpose of our study is to evaluate the efficacy and safety of vaginal assisted laparoscopic sacrocervicopexy with anterior colpotomy (VALSAC) for apical pelvic organ prolapse. We retrospectively reviewed the results of twenty-three women with stage III and IV prolapse treated with VALSAC between April 2017 and June 2019. With a mean follow-up of 20 months, apical pelvic organ prolapse was cured in 95.7 % of patients. There was no complication in terms of mesh exposure, persistent pain, hematoma, infection. The mean pre- and post-operative POP-Q scores were, for the Aa point, 1.61 +/- 1.82 cm and -1.96 +/- 0.87 cm (p < 0.01), for the C point, 2.87 +/- 1.6 cm and -5.26 +/- 1.86 cm (p < 0.01) for the Ap point, -1.43 +/- 0.89 cm and -2.09 +/- 0.59 cm (p < 0.01). VALSAC is a promising minimally invasive technique for pelvic floor reconstruction that appears to provide good outcomes. Content: The main purpose of our study is to evaluate the efficacy and safety of vaginal assisted laparoscopic sacrocervicopexy with anterior colpotomy (VALSAC) for apical pelvic organ prolapse.
  • PublicationOpen Access
    Effects of Apigenin on Experimental Ischemia/Reperfusion Injury in the Rat Ovary.
    (2017-09-29) SOYMAN, Z; KELEKCI, S; SAL, V; Şevket, OSMAN; BAYıNDıR, NİHAN; UZUN, H; ŞEVKET, OSMAN; BAYINDIR, NİHAN
    Background: Apigenin is a plant-derived compound belonging to the flavone class, which possess antioxidant, free-radical-scavenging and anti-inflammatory properties. Aims: To address the effects of apigenin on serum anti-mullerian hormone levels, tissue oxidative stress parameters and histopathological changes in ovarian ischemia/reperfusion injury. Study design: Animal experiment. Methods: Twenty-eight female Wistar albino rats were randomly separated into four sections: Sham operation (group 1), ischemia/reperfusion plus saline (group 2), ischemia/reperfusion plus dimethyl sulfoxide (group 3) and ischemia/reperfusion plus apigenin (group 4). In all ischemia/reperfusion groups, a bilateral adnexal 3-h period of ischemia was performed, followed by 3-h of reperfusion. A single dose of 15 mg/kg apigenin was given intraperitoneally 60 min before reperfusion in group 4. After 3-h of reperfusion, both ovaries were removed, and blood samples were collected. The main outcome measures were serum anti-mullerian hormone levels, ovarian tissue malondialdehyde, total nitric oxide, Cu/Zn superoxide dismutase, catalase and glutathione levels and histopathological damage scores. Results: The ovarian tissue nitric oxide level was significantly lower, and the glutathione level was significantly higher in group 4 compared with groups 2 and 3. There was no significant difference in anti-mullerian hormone levels among the three ischemia/reperfusion groups. The histopathological damage score was lower in group 4 than in groups 2 and 3 (p>0.05). Conclusion: Administration of apigenin has no significant protective effect on ovarian reserve and tissue damage in ovarian ischemia/reperfusion injury.